First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors
Publication
, Conference
Majewksi, S; Kheterpal, M; Nardone, B; Sable, K; West, DP; Lacouture, ME
Published in: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
2016
Duke Scholars
Published In
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN
0190-9622
Publication Date
2016
Volume
74
Issue
5
Start / End Page
AB250 / AB250
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Majewksi, S., Kheterpal, M., Nardone, B., Sable, K., West, D. P., & Lacouture, M. E. (2016). First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. In JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (Vol. 74, pp. AB250–AB250).
Majewksi, Sara, Meenal Kheterpal, Beatrice Nardone, Kimberly Sable, Dennis P. West, and Mario E. Lacouture. “First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors.” In JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74:AB250–AB250, 2016.
Majewksi S, Kheterpal M, Nardone B, Sable K, West DP, Lacouture ME. First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016. p. AB250–AB250.
Majewksi, Sara, et al. “First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors.” JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 74, no. 5, 2016, pp. AB250–AB250.
Majewksi S, Kheterpal M, Nardone B, Sable K, West DP, Lacouture ME. First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016. p. AB250–AB250.
Published In
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN
0190-9622
Publication Date
2016
Volume
74
Issue
5
Start / End Page
AB250 / AB250
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences